{"id":"W2048627371","doi":"10.1186/bcr3011","title":"Design of RESILIENCE: a phase 3 trial comparing capecitabine in combination with sorafenib or placebo for treatment of locally advanced or metastatic HER2-negative breast cancer","year":2011,"lang":"en","type":"article","venue":"Breast Cancer Research","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Bayer (Canada)","funders":"","keywords":"Capecitabine; Sorafenib; Medicine; Internal medicine; Placebo; Oncology; Breast cancer; Surgical oncology; Hazard ratio; HER2 negative; Metastatic breast cancer; Cancer; Confidence interval; Hepatocellular carcinoma; Colorectal cancer; Pathology; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005785835,0.0002716912,0.0009504361,0.00045568,0.00008651109,0.000008712968,0.000161545,0.0000676129,0.001560572],"category_scores_gemma":[0.00004442344,0.0001703238,0.00007911879,0.0009775541,0.0004474018,0.0001560931,0.00002989476,0.0001454492,0.000001732532],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001115663,"about_ca_system_score_gemma":0.002868027,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01562463,"about_ca_topic_score_gemma":0.01107019,"domain_scores_codex":[0.9974281,0.0003462353,0.0005695346,0.0004753819,0.0006027636,0.0005780298],"domain_scores_gemma":[0.9977087,0.0007022878,0.0002529844,0.0002594604,0.0008889997,0.0001875846],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9219335,0.008904209,0.003092044,0.000430245,0.0005981698,0.00009828898,0.003525243,0.0005802418,0.005247551,0.00003382955,0.0001544561,0.05540225],"study_design_scores_gemma":[0.8473775,0.05363251,0.02079242,0.001460651,0.000794574,0.0001986089,0.002322685,0.006706226,0.06608811,0.0001262449,0.0001086588,0.000391806],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9855114,0.0004358577,0.001438549,0.0007946859,0.00014143,0.010855,0.0006092454,0.00002541535,0.0001883693],"genre_scores_gemma":[0.9895156,0.0006478427,0.002392311,0.00001747585,0.00009041053,0.00619662,0.00002547249,0.00004428101,0.00107001],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07455596,"threshold_uncertainty_score":0.9993522,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2128159828587136,"score_gpt":0.4763384902362042,"score_spread":0.2635225073774906,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}